NASDAQ:HOOK Hookipa Pharma (HOOK) Stock Price, News & Analysis $4.17 +0.27 (+6.92%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Hookipa Pharma Stock (NASDAQ:HOOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hookipa Pharma alerts:Sign Up Key Stats Today's Range$3.90▼$4.3250-Day Range$3.65▼$5.6552-Week Range$3.41▼$11.30Volume22,601 shsAverage Volume57,705 shsMarket Capitalization$41.26 millionP/E RatioN/ADividend YieldN/APrice Target$44.67Consensus RatingBuy Company OverviewHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Read More… Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Hookipa Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks68th Percentile Overall ScoreHOOK MarketRank™: Hookipa Pharma scored higher than 68% of companies evaluated by MarketBeat, and ranked 370th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHookipa Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Hookipa Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hookipa Pharma is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hookipa Pharma is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHookipa Pharma has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Hookipa Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.45% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently decreased by 31.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHookipa Pharma does not currently pay a dividend.Dividend GrowthHookipa Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.45% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently decreased by 31.65%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News SentimentN/A News SentimentHookipa Pharma has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hookipa Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Hookipa Pharma is held by insiders.Percentage Held by Institutions63.88% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hookipa Pharma's insider trading history. Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HOOK Stock News HeadlinesHOOKIPA Pharma to Present Strong Preclinical HB-700 DatasetSeptember 24, 2024 | globenewswire.comHOOKIPA Pharma (NASDAQ:HOOK) Stock Quotes, Forecast and News SummarySeptember 11, 2024 | benzinga.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.October 17, 2024 | Weiss Ratings (Ad)HOOKIPA Pharma Announces Board of Directors ChangesAugust 30, 2024 | globenewswire.comHOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comHOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss ExpectationsAugust 11, 2024 | finance.yahoo.comBuy Rating and Price Target Increase for Hookipa Pharma Amid Clinical and Financial ProgressAugust 10, 2024 | markets.businessinsider.comHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 10, 2024 | finanznachrichten.deSee More Headlines HOOK Stock Analysis - Frequently Asked Questions How have HOOK shares performed this year? Hookipa Pharma's stock was trading at $8.10 on January 1st, 2024. Since then, HOOK shares have decreased by 48.5% and is now trading at $4.17. View the best growth stocks for 2024 here. How were Hookipa Pharma's earnings last quarter? Hookipa Pharma Inc (NASDAQ:HOOK) issued its earnings results on Thursday, August, 8th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.08. The firm earned $1.29 million during the quarter, compared to the consensus estimate of $5.68 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 36.81% and a negative net margin of 93.16%. When did Hookipa Pharma's stock split? Hookipa Pharma's stock reverse split before market open on Wednesday, July 10th 2024. The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Hookipa Pharma IPO? Hookipa Pharma (HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager. How do I buy shares of Hookipa Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Hookipa Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hookipa Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOOK CUSIPN/A CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$44.67 High Stock Price Target$60.00 Low Stock Price Target$24.00 Potential Upside/Downside+971.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net Margins-93.16% Pretax Margin-92.85% Return on Equity-36.81% Return on Assets-23.18% Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual Sales$52.16 million Price / Sales0.79 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book0.46Miscellaneous Outstanding Shares9,895,000Free Float11,657,000Market Cap$41.26 million OptionableOptionable Beta0.83 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:HOOK) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.